Spyryx Presents Data Ably Supporting SPX-101 as Potential Treatment for All CF Patients
Spyryx Biosciences recently presented preclinical data supporting the clinical benefits of its cystic fibrosis (CF) treatment candidate SPX-101, intended to improve lung function in all patients regardless of their underlying disease-causing mutation. The data, presented in four posters at the recent North American Cystic Fibrosis Conference (NACFC) in Indianapolis,…